Citations (36)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (5)
Adebowale A. Alade, Samad A. Ahmed, Somdutt Mujwar, Babatomiwa Kikiowo, Precious A. Akinnusi, Samuel O. Olubode, Oluwafeyisayomi M. Olufemi & Abass A. Ohilebo. (2024) Identification of levomenthol derivatives as potential dipeptidyl peptidase-4 inhibitors: a comparative study with gliptins. Journal of Biomolecular Structure and Dynamics 42:8, pages 4029-4047.
Read now
Read now
Ofri Mosenzon, Eden M. Miller & Mark L. Warren. (2020) Oral semaglutide in patients with type 2 diabetes and cardiovascular disease, renal impairment, or other comorbidities, and in older patients. Postgraduate Medicine 132:sup2, pages 37-47.
Read now
Read now
Frank Lavernia & Lawrence Blonde. (2020) Clinical review of the efficacy and safety of oral semaglutide in patients with type 2 diabetes compared with other oral antihyperglycemic agents and placebo. Postgraduate Medicine 132:sup2, pages 15-25.
Read now
Read now
Stephen A. Brunton, Ofri Mosenzon & Eugene E. Wright Jr. (2020) Integrating oral semaglutide into clinical practice in primary care: for whom, when, and how?. Postgraduate Medicine 132:sup2, pages 48-60.
Read now
Read now
Eugene E. Wright Jr & Vanita R. Aroda. (2020) Clinical review of the efficacy and safety of oral semaglutide in patients with type 2 diabetes considered for injectable GLP-1 receptor agonist therapy or currently on insulin therapy. Postgraduate Medicine 132:sup2, pages 26-36.
Read now
Read now
Articles from other publishers (31)
Sixu Li, Feng Xiong, Songbo Zhang, Jinghua Liu, Guangping Gao, Jun Xie & Yi Wang. (2024) Oligonucleotide therapies for nonalcoholic steatohepatitis. Molecular Therapy - Nucleic Acids 35:2, pages 102184.
Crossref
Crossref
C. Formichi, W. Baronti, G. de Gennaro, M. Cerrai Ceroni, L. Nigi, L. Rizzo & F. Dotta. (2024) Real-world use of oral versus subcutaneous semaglutide in a cohort of type 2 diabetic patients: which option to which patient?. Journal of Endocrinological Investigation.
Crossref
Crossref
Xi Tan, Victoria Divino, James Amamoo, Lin Xie, Katharine B. Coyle, Cory L. Gamble, Mico Guevarra, Yurek Paprocki & Aaron A. King. (2024) Real-World Effectiveness of Once-Weekly Glucagon-Like Peptide-1 Receptor Agonists (OW GLP-1RAs) in Comparison with Dipeptidyl Peptidase-4 Inhibitors (DPP-4is) for Glycemic Control and Weight Outcomes in Type 2 Diabetes Mellitus (RELATE). Clinical Drug Investigation 44:4, pages 271-284.
Crossref
Crossref
Wenhui Qin, Jun Yang, Chao Deng, Qinjuan Ruan & Kai Duan. (2023)
Efficacy and safety of semaglutide 2.4 mg for weight loss in overweight or obese adults without diabetes: An updated systematic review and meta‐analysis including the 2‐year
STEP
5 trial
. Diabetes, Obesity and Metabolism 26:3, pages 911-923.
Crossref
Crossref
Faria Athar, Muskan Karmani & Nicole M. Templeman. (2024) Metabolic hormones are integral regulators of female reproductive health and function. Bioscience Reports 44:1.
Crossref
Crossref
Dima Abdelmannan, Manal AlBuflasa, Heitham Ajlouni, Marwan Zidan, Farya Rahman, Muhammad Hamed Farooqi & A. Enrique Caballero. (2024) Institutional experience on the impact of glucagon-like peptide-1 agonists (GLP-1) on glycemic control and weight loss in patients with type 2 diabetes at the Dubai Diabetes Center, United Arab Emirates. Diabetes Research and Clinical Practice 207, pages 111045.
Crossref
Crossref
A. N. Arefeva, V. V. Banko, M. O. Sadovskikh & S. M. Noskov. (2023) Pharmacokinetics of first semaglutid drug in Russian Federation: results of open-label randomized clinical trial. Meditsinskiy sovet = Medical Council:16, pages 77-82.
Crossref
Crossref
Shahzad Irfan, Humaira Muzaffar, Imran Mukhtar, Farhat Jabeen & Haseeb Anwar. 2023. Beta Cells in Health and Disease. Beta Cells in Health and Disease.
Sonnal Lohia, Justyna Siwy, Emmanouil Mavrogeorgis, Susanne Eder, Stefanie Thöni, Gert Mayer, Harald Mischak, Antonia Vlahou & Vera Jankowski. (2023) Exploratory Study Analyzing the Urinary Peptidome of T2DM Patients Suggests Changes in ECM but Also Inflammatory and Metabolic Pathways Following GLP-1R Agonist Treatment. International Journal of Molecular Sciences 24:17, pages 13540.
Crossref
Crossref
Valeh Mirzazada, Sadagat Sultanova, Natavan Ismayilova, Aygun Huseynova, Gulnara Nurmammadova, Sevil Ismayilova & Aygun Aliyeva. 2023. Novel Pathogenesis and Treatments for Cardiovascular Disease. Novel Pathogenesis and Treatments for Cardiovascular Disease.
Xiao-Min Huang, Xing Zhong, Yi-Jun Du, Yan-Yun Guo & Tian-Rong Pan. (2023) Effects of glucagon-like peptide-1 receptor agonists on glucose excursion and inflammation in overweight or obese type 2 diabetic patients. World Journal of Diabetes 14:8, pages 1280-1288.
Crossref
Crossref
Muhammed Majeed, Narayanan K. Narayanan, Lakshmi Mundkur, Priji Prakasan & Kalyanam Nagabhushanam. (2023) Super Fruit Amla (Emblica officinalis, Gaertn) in Diabetes Management and Ensuing Complications: A Concise Review. Nutraceuticals 3:3, pages 329-352.
Crossref
Crossref
Upendra GuntaDilipkumar Reddy Kandula, Santosh Kapil Kumar Gorti, Gangadhar P Vadla, Gopi KodiyalaMastan M. (2023) Investigating the Binding Efficacy of Snake Venom Proteins as GLP-1 Analogs for Diabetes mellitus Management: An In silico Study. Oriental Journal Of Chemistry 39:3, pages 581-591.
Crossref
Crossref
Yuanzhi Yao, Xiaoying Li, Xiaoqin Yang, Hai Mou & Lin Wei. (2023) Dihydromyricetin promotes GLP-1 release and glucose uptake by STC-1 cells and enhances the effects of metformin upon STC-1 cells and diabetic mouse model. Tissue and Cell 82, pages 102108.
Crossref
Crossref
Corinna Schulz, Cecilia Vezzani & Nils B. Kroemer. (2023) How gut hormones shape reward: A systematic review of the role of ghrelin and GLP-1 in human fMRI. Physiology & Behavior 263, pages 114111.
Crossref
Crossref
Samuele Venturi, Mirko Marino, Iolanda Cioffi, Daniela Martini, Cristian Del Bo’, Simone Perna, Patrizia Riso, Dorothy Klimis-Zacas & Marisa Porrini. (2023) Berry Dietary Interventions in Metabolic Syndrome: New Insights. Nutrients 15:8, pages 1906.
Crossref
Crossref
Paolo Basile, Andrea Igoren Guaricci, Giuseppina Piazzolla, Sara Volpe, Alfredo Vozza, Marina Benedetto, Maria Cristina Carella, Daniela Santoro, Francesco Monitillo, Andrea Baggiano, Saima Mushtaq, Laura Fusini, Fabio Fazzari, Cinzia Forleo, Nunziata Ribecco, Gianluca Pontone, Carlo Sabbà & Marco Matteo Ciccone. (2023) Improvement of Left Ventricular Global Longitudinal Strain after 6-Month Therapy with GLP-1RAs Semaglutide and Dulaglutide in Type 2 Diabetes Mellitus: A Pilot Study. Journal of Clinical Medicine 12:4, pages 1586.
Crossref
Crossref
P.P. Mohanan & Pankaj Jariwala. (2023) HOW did GLP-1RAs bring about a paradigm shift in the guidelines of managing T2DM: A path to gluco-cardio Centricity. Indian Heart Journal 75:1, pages 1-8.
Crossref
Crossref
Mansoor Husain, Agostino Consoli, Alessandra De Remigis, Anna Sina Pettersson Meyer, Søren Rasmussen & Stephen Bain. (2022) Semaglutide reduces cardiovascular events regardless of metformin use: a post hoc subgroup analysis of SUSTAIN 6 and PIONEER 6. Cardiovascular Diabetology 21:1.
Crossref
Crossref
Hamlet Gasoyan & David B. Sarwer. (2022) Addressing insurance‐related barriers to novel antiobesity medications: Lessons to be learned from bariatric surgery. Obesity 30:12, pages 2338-2339.
Crossref
Crossref
Noriko Tagawa, Honoka Ogura, Hikaru Miyawaki, Akihiro Asakawa & Ikuo Kato. (2022) Intraperitoneal administration of nesfatin‑1 stimulates glucagon‑like peptide‑1 secretion in fasted mice. Molecular Medicine Reports 27:1.
Crossref
Crossref
Maja Cigrovski Berkovic, Tanja Rezic, Ines Bilic-Curcic & Anna Mrzljak. (2022) Semaglutide might be a key for breaking the vicious cycle of metabolically associated fatty liver disease spectrum?. World Journal of Clinical Cases 10:20, pages 6759-6768.
Crossref
Crossref
Kaisang Lin, Wei Zhang, Fei He & Jie Shen. (2022) Evaluation of the Clinical Efficacy of the Treatment of Overweight and Obesity in Type 2 Diabetes Mellitus by the Telemedicine Management System Based on the Internet of Things Technology. Computational Intelligence and Neuroscience 2022, pages 1-12.
Crossref
Crossref
Sanjay Kalra & Nitin Kapoor. (2022) Oral Semaglutide: Dosage in Special Situations. Diabetes Therapy 13:6, pages 1133-1137.
Crossref
Crossref
Juanjuan Zhao, Pengcheng Xu, Xiujuan Liu, Xiaobo Ji, Minjie Li, Dev Sooranna, Xiaosheng Qu, Wencong Lu & Bing Niu. (2022) Application of Machine Learning Methods for the Development of Antidiabetic
Drugs. Current Pharmaceutical Design 28:4, pages 260-271.
Crossref
Crossref
Raja Gopal Reddy Mooli, Dhanunjay Mukhi, Anil K. Pasupulati, Simon S. Evers, Ian J. Sipula, Michael Jurczak, Randy J. Seeley, Yatrik M. Shah & Sadeesh K. Ramakrishnan. (2022) Intestinal HIF-2α Regulates GLP-1 Secretion via Lipid Sensing in L-Cells. Cellular and Molecular Gastroenterology and Hepatology 13:4, pages 1057-1072.
Crossref
Crossref
Naveed Sattar, Matthew M Y Lee, Søren L Kristensen, Kelley R H Branch, Stefano Del Prato, Nardev S Khurmi, Carolyn S P Lam, Renato D Lopes, John J V McMurray, Richard E Pratley, Julio Rosenstock & Hertzel C Gerstein. (2021) Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of randomised trials. The Lancet Diabetes & Endocrinology 9:10, pages 653-662.
Crossref
Crossref
Xin Zhao, Minghe Wang, Zhitong Wen, Zhihong Lu, Lijuan Cui, Chao Fu, Huan Xue, Yunfeng Liu & Yi Zhang. (2021) GLP-1 Receptor Agonists: Beyond Their Pancreatic Effects. Frontiers in Endocrinology 12.
Crossref
Crossref
Hakan KORKMAZ. (2021) COVID-19 ve Diabetes Mellitus YönetimiCOVID-19 and Diabetes Mellitus Management. SDÜ Tıp Fakültesi Dergisi 28:COVİD-19 ÖZEL SAYI, pages 171-175.
Crossref
Crossref
Matthew C. Riddle. (2021) The current schemes of insulin therapy: Pro and contra. Diabetes Research and Clinical Practice 175, pages 108817.
Crossref
Crossref
Joanna Michałowska, Ewa Miller-Kasprzak & Paweł Bogdański. (2021) Incretin Hormones in Obesity and Related Cardiometabolic Disorders: The Clinical Perspective. Nutrients 13:2, pages 351.
Crossref
Crossref